Major Events - Different Group (06090) has a public offering with a subscription rate of 3317.47 times the upper limit price [1] - Botai Che Lian (02889) plans to globally offer 10.4369 million H-shares from September 22 to September 25 [1] - Changhong Jiahua (03991) received a privatization offer from Changhong Group at a premium of approximately 32.93%, with resumption of trading on September 23 [1] - Huajian Medical (01931) signed a strategic cooperation agreement with Chuangsheng Group-B (06628) involving the tokenization of a $1.5 billion innovative drug pipeline asset [1] - Gilead Sciences-B (01672) reported that ASC47 combined with Semaglutide showed a weight loss effect improvement of up to 56.2% compared to Semaglutide alone in obese subjects [1] - Fosen Pharmaceutical (01652) plans to sell all equity of Henan Fosen Smart Energy Technology for 73 million yuan [1] - Maiyue Technology (02501) entered into strategic cooperation agreements with NetEase Youdao and Ferry International [1] - Zhongchuang Zhiling (00564) intends to invest 270 million yuan to establish Yaxinke Thermal Management Technology (Yizheng) Co., Ltd. to enhance market competitiveness in automotive thermal management systems [1] - Garmin Group Holdings (01271) plans to sell a portfolio of four data center projects for 5.25 billion HKD [1] Buybacks and Increases - Tencent Holdings (00700) repurchased 862,000 shares for 550 million HKD on September 22 [1] - Standard Chartered Group (02888) repurchased 517,100 shares for 7.3877 million GBP on September 19 [1] - Midea Group (00300) repurchased 3.415 million A-shares for 250 million yuan on September 22 [1] - Anta Sports (02020) repurchased 2.12 million shares for 199 million HKD on September 22 [1] - Kuaishou-W (01024) repurchased 1 million shares for 73.7998 million HKD on September 22 [1] - Heng Rui Pharmaceutical (01276) repurchased 656,000 A-shares for 45.7493 million yuan on September 19 [1] - Shenzhen Expressway Company (00548) received an increase of 25.38 million H-shares from shareholder Yunsong Capital [1]

Core Insights - The establishment of the ETHK building by Huajian Medical marks a significant milestone in the development of Real World Asset (RWA) digital technology, positioning Nanjing as a global hub for RWA technology [1][2] - Huajian Medical's strategy focuses on transforming into a digital infrastructure provider, with the ETHK building serving as a physical manifestation of this strategy [2][3] Group 1: RWA Technology and Nanjing Hub - RWA, or Real World Asset tokenization, is emerging as a hot area in global fintech, with a projected total locked value (TVL) of $12.5 billion by June 2025, representing a 124% increase from 2024 [2] - The establishment of ETHK Inc. and ETHK HOLDINGS LIMITED indicates Huajian Medical's commitment to the digital industry infrastructure [2] - Nanjing's location is strategic, as the Yangtze River Delta is a core area for China's biopharmaceutical industry, accounting for one-third of the national industry scale [2] Group 2: Strategic Collaborations - Huajian Medical signed strategic cooperation agreements with four companies, including a $1.5 billion RWA tokenization deal with Chuangsheng Group for six innovative drug pipeline assets [4][7] - The collaboration with Chuangsheng Group aims to integrate their innovative drug assets into a U.S. entity for potential RWA tokenization [4] - Additional partnerships with Shenzhen Yuanli Life Sciences, Jiangsu Mailian Technology, and Beijing Guofeng Law Firm create a comprehensive ecosystem from biopharmaceutical innovation to legal compliance [7] Group 3: Industry Transformation and Market Potential - The launch of the RWA technology base and strategic partnerships signify the scaling of Huajian Medical's ETHK chain financial ecosystem [8] - The global RWA market is projected to reach $16.1 trillion by 2030, representing 10% of global GDP [8] - RWA tokenization in the biopharmaceutical sector allows for the early locking of R&D value, providing new funding channels without equity dilution [8][9] Group 4: Altruistic Ecosystem and New Economic Paradigm - Huajian Medical's "altruistic" approach enables partners to optimize asset structures and innovate financing models [9] - The ETHK building's opening symbolizes a new economic paradigm, enhancing asset liquidity and capital allocation efficiency [10] - The digital economy wave signifies the beginning of a new era for global asset circulation in China [10]

Group 1 - The establishment of the ETHK building marks a significant milestone for the company, representing the physical realization of its ETHK blockchain financial ecosystem strategy and positioning Nanjing as a global hub for Real World Asset (RWA) technology [1][4][14] - The RWA sector is transitioning from concept validation to large-scale application, with a projected total value locked (TVL) of $12.5 billion by June 2025, reflecting a 124% increase from 2024 [4] - The ETHK building will serve as a core base for RWA digital technology research and ecosystem empowerment, housing over 5,000 technical experts and various research facilities [7][14] Group 2 - The company has signed strategic cooperation agreements with four enterprises, including a $1.5 billion RWA tokenization deal with Chuangsheng Group, integrating six core innovative drug pipeline assets into its U.S. entity [8][13] - The partnerships aim to create a comprehensive ecosystem from biopharmaceutical innovation to legal compliance, enhancing the efficiency of asset value discovery and circulation through digitalization [13][14] - The company's "so-in-so" model aims to build a top-tier global trading ecosystem for RWA across multiple industries, providing a one-stop solution for asset digital transformation [13][14] Group 3 - The launch of the ETHK building and the strategic partnerships signify the company's transition into a scalable phase of its ETHK blockchain financial ecosystem strategy [14][15] - The RWA tokenization path chosen by the company is seen as forward-looking, with predictions estimating the global RWA market to reach $16.1 trillion by 2030, accounting for 10% of global GDP [15] - The company's "altruistic" approach allows partners to optimize their asset structures and innovate financing models, facilitating the development of cutting-edge therapies and improving patient accessibility [15][16]

Group 1 - A new asset paradigm is emerging globally, driven by the tokenization of Real World Assets (RWA) using blockchain technology, enabling continuous global liquidity and financing [1][17] - The ETHK Building, launched by Huajian Medical in Nanjing, is the world's first RWA technology base, marking a significant step in the large-scale implementation of RWA technology in China [3][8] - The ETHK Building spans approximately 70,000 square meters, with the main building covering 35,000 square meters, making it the largest and most comprehensive RWA research and innovation base globally [3][7] Group 2 - The establishment of the ETHK Building addresses the dual challenges of technical infrastructure and regulatory frameworks that have hindered the large-scale implementation of RWA [3][8] - The building is designed as a dual-purpose infrastructure, serving as both a center for R&D and a base for trusted technology development and output [3][7] - The facility is expected to gather over 5,000 technical experts and engineers, forming one of the strongest RWA research teams globally [7] Group 3 - Huajian Medical's "ETHK Global RWA Trading - Exchange within an Exchange" model aims to fill the service gap in China's RWA market, providing a comprehensive solution for asset selection, structural design, compliance issuance, and liquidity management [8][9] - This model is particularly valuable in the healthcare sector, facilitating innovative financing for drug development and global market expansion [9][10] Group 4 - Huajian Medical has entered a phase of scaling its "Exchange within an Exchange" model, signing strategic cooperation agreements with four key partners across various sectors, including pharmaceuticals and legal compliance [9][10] - The collaboration with Chuangsheng Group involves the tokenization of innovative drug pipeline assets, with a total valuation exceeding $1.5 billion, representing cutting-edge research in cancer treatment [10] Group 5 - The launch of the RWA Protocol White Paper addresses key challenges in the current financial system, focusing on creating a foundational protocol for the issuance and trading of real-world assets [10][15] - The RWA Protocol aims to enhance settlement efficiency, transparency, and compliance in capital markets, facilitating cross-border asset allocation [15] Group 6 - Huajian Medical's strategy aligns with national policies promoting the market-oriented operation and securitization of intellectual property, as highlighted in recent government initiatives [16] - The global RWA market is projected to reach $16.1 trillion by 2030, representing 10% of global GDP, indicating significant growth potential [16] Group 7 - The completion of the ETHK Building symbolizes a new financial paradigm and showcases China's innovative capabilities in integrating blockchain with the real economy [17] - As more assets are tokenized through RWA, a more open, efficient, and inclusive global asset allocation era is anticipated, with Huajian Medical leading the charge [17]

今年以来，港股市场的加密货币概念股普遍实现大涨，云锋金融（00376.HK）、国泰君安国际（01788.HK）、国富量子（00290.HK）等多股录得翻倍飙 升。 不过，板块内涨势最好的其实是跨界而来的华检医疗（01931.HK）。 数据显示，自今年7月中旬以来，此前"平平无奇"的华检医疗就像"打了鸡血"一样，迎来持续疯涨，其股价在年内已累涨近490%。 股价飙升背后，离不开华检医疗在Web3赛道频频碰撞出利好的消息面。 从卖诊断试剂到建 Web3 交易所：3个月火力全开 华检医疗和其附属公司是国内IVD（体外诊断）产品的领先分销商，同时也参与其自有品牌IVD产品的研究、开发、生产及销售。 而在今年下半年，体外诊断企业开始跨界区块链领域。 7月17日，华检医疗发布公告称，公司正积极推进一项具有里程碑意义的战略举措，即构建以医疗创新药高科技资产为核心的"NewCo+RWA"Web3交易所生 态，该生态将命名为"IVDNewCo Exchange"（下称"交易所"），并配套发行专有稳定币（IVDDollar）（"IVDD"）。 为支撑该生态的全球运作，华检医疗已启动多项跨境合规化工作，包括香港稳定币牌照申请、美国 ...

核校：孙萍 华检医疗将为管线资产提供涵盖数字化发起、可信上链、合规发行及流动性对接的全流程技术解决方 案。双方将于9月22日上午在南京举行战略合作协议签约仪式。 公司表示，此次合作完成后将为高价值管线提前锁定研发价值，提供全球资本配置新渠道，并加速疗法 可及性。同时公司提醒，该协议不具法律约束力，涉及区块链、数字资产及生物医药等新兴领域，具有 高风险、高波动性及监管不确定性等特点，投资者应审慎行事。 中证智能财讯 华检医疗（01931）9月22日早间公告，公司与创胜集团（06628）及其附属公司签署战略 合作协议，共同探索创新药管线资产RWA代币化。创胜集团将其六个核心创新药管线资产整合至美国 实体，并通过华检医疗构建的ETHK全球创新药知识产权RWA交易所进行潜在代币化合作，该等资产总 估值超过15亿美元。 本次合作涉及六大创新肿瘤药物管线，包括同类首创抗GREMLIN-1抗体TST003、PD-L1/TGF-β双功能 融合蛋白TST005、靶向PD1-VEGF及GREMLIN-1的三特异性抗体TST786，以及三个处于临床前阶段的 抗体偶联药物TST105、TST106和TST013。这些管线涵盖双抗、三 ...

Core Insights - The strategic cooperation agreement between Huajian Medical and Transcenta Holding aims to explore the potential RWA tokenization of six core innovative drug pipeline assets valued at over $1.5 billion, representing cutting-edge research in the global oncology treatment field [1][2] - This collaboration marks a significant milestone in the integration of technology and finance, as it represents the first issuance of high-value innovative drug intellectual property assets in RWA form in the capital market [1][2] Summary by Sections Strategic Cooperation - Huajian Medical and its subsidiaries have entered into a strategic cooperation agreement with Transcenta Holding and its subsidiaries to explore RWA tokenization of innovative drug pipeline assets [1] - The six core assets involved are TST003, TST005, TST786, TST105, TST106, and TST013, which are integrated into Transcenta Oncology Inc. in the U.S. [1] RWA Tokenization Benefits - The RWA tokenization aims to lock in the research value of high-value pipelines, allowing issuers to efficiently activate top pipeline assets at various clinical stages without diluting equity [2] - It provides a new channel for global capital allocation, offering professional investors a transparent, compliant, and efficient opportunity to invest in cutting-edge innovative drug intellectual property assets [2] - The innovative financing model is expected to accelerate the development of advanced therapies, ultimately benefiting global patients and addressing urgent unmet medical needs [2] Future Growth and Collaboration - The collaboration is anticipated to generate significant synergies, injecting strong momentum into the sustainable business growth and financial performance of the group [2] - The group will work closely with Transcenta to ensure the successful implementation of the project to high standards [2]

智通财经APP讯，华检医疗(01931)发布公告，公司及公司附属公司ETHK Inc及ETHK HOLDINGS LIMITED与创胜集团医药有限公司Transcenta Holding Limited(创胜集团，股票代号：06628.HK)及其附 属公司Transcenta Oncology Inc. (US)(统称创胜方)就潜在的创新药管线资产RWA代币化相关事项订立战 略合作协议。 据此，创胜方将其旗下六个核心创新药管线资产(即TST003,TST005,TST786,TST105,TST106及TST013) 整合至其美国实体Transcenta Oncology Inc. (US)，并利用集团专业构建的ETHK全球创新药知识产权 RWA交易所，与华检医疗就资产的潜在RWA代币化进行合作。该等资产总估值超过15亿美元，代表全 球肿瘤治疗领域最前沿的研发方向与高技术壁垒。 集团将为该等管线资产提供涵盖数字化发起、可信上链、合规发行及流动性对接的全流程技术解决方 案。本次合作标志着全球首批高价值创新药知识产权资产以RWA形式正式在资本市场发售/推出，是一 项标志着科技与金融深度融合的里程碑事件。 提供全球 ...

Core Viewpoint - The strategic cooperation agreement between Huajian Medical and Chuangsheng Group-B marks a significant milestone in the integration of technology and finance, focusing on the tokenization of innovative drug pipeline assets valued at over $1.5 billion [1] Group 1: Strategic Cooperation - Huajian Medical and its subsidiaries ETHK Inc and ETHK HOLDINGS LIMITED have entered into a strategic cooperation agreement with Chuangsheng Group-B and its subsidiary Transcenta Oncology Inc. [1] - The agreement involves the integration of six core innovative drug pipeline assets into Transcenta Oncology Inc. [1] Group 2: Asset Valuation and Technology Solutions - The total valuation of the integrated assets exceeds $1.5 billion, representing cutting-edge research directions and high technical barriers in the global oncology treatment field [1] - The group will provide a comprehensive technical solution covering digital initiation, trusted on-chain processes, compliant issuance, and liquidity connection for these pipeline assets [1] Group 3: Market Impact - This cooperation signifies the official launch of high-value innovative drug intellectual property assets in the capital market in the form of RWA, highlighting a milestone event in the deep integration of technology and finance [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公 司） （股份代號：1931） 自願性公告 與 創 勝 集 團 醫 藥 有 限 公 司（06628.HK）簽 署 涉15億美元 創新藥管線資產RWA代幣化之戰略合作協議 本 公 告 乃 由 華 檢 醫 療 控 股 有 限 公 司（「本公司」或「華檢醫療」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，旨 在 向 股 東 及 潛 在 投 資 者 提 供 本 集 團 業 務 發 展 的 最 新 資 料。 一、合作概況與六大創新藥管線亮點 本 公 司 董 事 會（「董事會」）欣 然 宣 佈，本 公 司 及 本 公 司 附 屬 公 司ETHK Inc及 ETHK HOLDINGS LIMITED與創勝集團醫藥有限公司Transcenta ...